SYNB:NYE-Putnam Biorevolution ETF (USD)

ETF | Others |

Last Closing

USD 32.8607

Change

0.00 (0.00)%

Market Cap

USD 5.43M

Volume

267.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund invests mainly in common stocks (growth or value stocks or both) of companies worldwide of any size with a focus on "biology revolution" companies. From time to time, the fund may invest a significant portion of its assets in companies in one or more related industries or sectors, including the health care, consumer discretionary, consumer staples, biotechnology and materials sectors. The fund is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-21 )

ETFs Containing SYNB

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.92% 68% D+ 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.92% 64% D 59% D-
Trailing 12 Months  
Capital Gain 22.51% 67% D+ 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.51% 62% D 60% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 5.11% 75% C 56% F
Dividend Return 5.11% 70% C- 48% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 6.64% 67% D+ 86% B+
Risk Adjusted Return 77.04% 86% B+ 88% B+
Market Capitalization 5.43M 13% F 4% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.